How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains unacceptably high. Measurable (minimal) residual disease (MRD) after allo-HCT may be used as a predictor of impending relapse and should be part of routin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-05, Vol.135 (19), p.1639-1649
1. Verfasser:	Spyridonidis, Alexandros
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adult Antineoplastic Agents - therapeutic use Female Graft vs Host Disease - drug therapy Graft vs Host Disease - etiology Graft vs Host Disease - pathology Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunosuppressive Agents - therapeutic use Leukemia - pathology Leukemia - therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - etiology Neoplasm Recurrence, Local - pathology Neoplasm, Residual - drug therapy Neoplasm, Residual - etiology Neoplasm, Residual - pathology Prognosis Transplantation, Homologous Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!